^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    mesna

    Company:
    Generic mfg.
    Drug class:
    Antioxidant
    Related drugs:
    7d
    CD45RA-depleted CD19-CAR T Cell Consolidation After TCR??+ T Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma (clinicaltrials.gov)
    P1, N=60, Not yet recruiting, St. Jude Children's Research Hospital
    New P1 trial
    |
    cyclophosphamide • melphalan • fludarabine IV • mesna • thiotepa • Neupogen (filgrastim)
    22d
    Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1/2, N=24, Active, not recruiting, St. Jude Children's Research Hospital | Trial completion date: Jul 2025 --> Jul 2026
    Trial completion date
    |
    cyclophosphamide • fludarabine IV • mesna • SJCAR19
    1m
    A Phase II Study of Durvalumab, Doxorubicin, and Ifosfamide in Recurrent and/or Metastatic Pulmonary Sarcomatoid Carcinoma (KCSG LU-19-24). (PubMed, Clin Lung Cancer)
    Durvalumab combined with doxorubicin and ifosfamide suggested clinical activity in recurrent and/or metastatic PSC. Larger studies are warranted to confirm benefits and refine treatment strategies.
    P2 data • Journal
    |
    PD-L1 (Programmed death ligand 1)
    |
    Imfinzi (durvalumab) • doxorubicin hydrochloride • ifosfamide • mesna
    1m
    The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation (clinicaltrials.gov)
    P1/2, N=260, Recruiting, National Cancer Institute (NCI) | Trial completion date: Jul 2027 --> Jun 2028
    Trial completion date
    |
    IGH (Immunoglobulin Heavy Locus) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    cyclophosphamide • sirolimus • melphalan • fludarabine IV • mesna • Neupogen (filgrastim)
    1m
    Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma (clinicaltrials.gov)
    P3, N=479, Active, not recruiting, Children's Oncology Group | Trial completion date: Dec 2025 --> Mar 2026
    Trial completion date
    |
    cisplatin • carboplatin • cyclophosphamide • etoposide IV • vincristine • mesna • Neupogen (filgrastim)
    2ms
    IS-free Treg HaploHCT (clinicaltrials.gov)
    P1, N=30, Recruiting, Dana-Farber Cancer Institute | N=20 --> 30 | Trial completion date: Dec 2030 --> Aug 2029 | Trial primary completion date: Dec 2029 --> Aug 2028
    Enrollment change • Trial completion date • Trial primary completion date
    |
    TP53 (Tumor protein P53) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
    |
    TP53 mutation
    |
    cyclophosphamide • melphalan • fludarabine IV • mesna • thiotepa
    2ms
    CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML) (clinicaltrials.gov)
    P1, N=108, Recruiting, St. Jude Children's Research Hospital | N=56 --> 108
    Enrollment change
    |
    CD123 (Interleukin 3 Receptor Subunit Alpha) • IL3RA (Interleukin 3 Receptor Subunit Alpha)
    |
    Rituxan (rituximab) • cyclophosphamide • fludarabine IV • mesna • CD123-CAR T cell therapy
    2ms
    Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma (clinicaltrials.gov)
    P1/2, N=35, Recruiting, Washington University School of Medicine | Trial completion date: Jan 2028 --> Jan 2029 | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial completion date • Trial primary completion date
    |
    ifosfamide • Hepacid (pegargiminase) • mesna
    3ms
    "Ewing's sarcoma of the duodenum: a rare gastrointestinal presentation": case report and review of literature. (PubMed, World J Surg Oncol)
    The patient had been receiving post-surgical adjuvant therapy and has completed four cycles of VAC (vincristine dactinomycin cyclophosphamide) and two cycles of VIME (Vincristine, Ifosfamide, Mesna, and Etoposide). A follow up PET scanning every three months initially would help to target early recurrences and the interval can be increased after 2 years. Also emerging techniques like liquid biopsies is becoming increasingly relevant for detection of recurrences and metastasis.
    Review • Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • EWSR1 (EWS RNA Binding Protein 1) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • VIM (Vimentin) • CD99 (CD99 Molecule) • SYP (Synaptophysin)
    |
    cyclophosphamide • ifosfamide • etoposide IV • vincristine • dactinomycin • mesna
    3ms
    IS-free Treg HaploHCT (clinicaltrials.gov)
    P1, N=20, Recruiting, Dana-Farber Cancer Institute | Trial completion date: Dec 2027 --> Dec 2030 | Trial primary completion date: Dec 2025 --> Dec 2029
    Trial completion date • Trial primary completion date
    |
    TP53 (Tumor protein P53) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
    |
    TP53 mutation
    |
    cyclophosphamide • fludarabine IV • mesna • thiotepa
    4ms
    A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT (clinicaltrials.gov)
    P2, N=160, Recruiting, Children's Oncology Group | Active, not recruiting --> Recruiting
    Enrollment open
    |
    NF1 (Neurofibromin 1)
    |
    AFP elevation
    |
    carboplatin • cyclophosphamide • ifosfamide • etoposide IV • mesna • thiotepa • Neulasta (pegfilgrastim) • Neupogen (filgrastim)
    4ms
    A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT (clinicaltrials.gov)
    P2, N=160, Active, not recruiting, Children's Oncology Group | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    NF1 (Neurofibromin 1)
    |
    AFP elevation
    |
    carboplatin • cyclophosphamide • ifosfamide • etoposide IV • mesna • thiotepa • Neulasta (pegfilgrastim) • Neupogen (filgrastim)